Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients with Spasticity
2017-004101-40Phase 3Completed
- Sponsor
- Osmotica Pharmaceuticals
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of arbaclofen in multiple sclerosis (MS), sponsored by Osmotica Pharmaceuticals. Started Jan 2018; status: completed.
02
Drugs
arbaclofen
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-004101-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004101-40.